Skip to main content
Top
Published in: Journal of General Internal Medicine 1/2011

01-01-2011 | Letters

Deeper Problems in the Marketing of Drugs

Author: Michael R. Grey, MD, MPH

Published in: Journal of General Internal Medicine | Issue 1/2011

Login to get access

Excerpt

To the Editors:—Kudos to Drs. Schiff and Norsigian for an eloquent summary of the real and potential harm to our patients of the pervasive influence of pharmaceutical marketing in health care and patient safety1. Patients and providers alike are inundated on a daily basis by attractive advertisements and (often) attractive pharmaceutical representatives whose primary purpose is to promote sales often under the guise of education. I do not disagree fundamentally with any of the author’s recommendations for improving this situation, but they should have gone further by insisting that we as physicians must be more skeptical and more scrupulous in doing our homework before prescribing the “latest and greatest” medications being touted in the media or by local pharmaceutical representatives. Most of us know that it is relatively uncommon for any new medication to be so overwhelmingly superior to an older (and often less expensive) medication with an established track record of efficacy and safety that a rapid change in prescribing practices is justified. Primum non nocere—above all do no harm—is one of those axioms often cited but less frequently practiced. We should remember this admonition. My usual response to patients who request a prescription for a novel or new medication is that I tend to be a late adopter when it comes to drugs in particular. The vast majority are reassured when I explain to them that there are enough high profile examples where downstream risks were found well after a medication has been widely prescribed to justify what one of my patients jokingly referred to as the “Canadian” style of practice. All of the accrediting bodies in undergraduate, graduate, and continuing medical education have recognized the potential harms of unfettered pharmaceutical industry access to learners across the spectrum of medical education and have crafted increasingly strict guidelines for such interactions. In the new consumer-driven world in which we live and practice, physicians must exercise caution, responsibility, and knowledgeable authority in talking to patients about the “best and safest treatment.” One might even go so far as to say that it is—at least sometimes—a matter of life or death. …
Literature
1.
go back to reference Schiff G, Norsigian J. Estrogen implants: embodiments of deeper problems in the marketing of drugs. JGIM. 2010;25(9):893–94.CrossRefPubMed Schiff G, Norsigian J. Estrogen implants: embodiments of deeper problems in the marketing of drugs. JGIM. 2010;25(9):893–94.CrossRefPubMed
Metadata
Title
Deeper Problems in the Marketing of Drugs
Author
Michael R. Grey, MD, MPH
Publication date
01-01-2011
Publisher
Springer-Verlag
Published in
Journal of General Internal Medicine / Issue 1/2011
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-010-1531-6

Other articles of this Issue 1/2011

Journal of General Internal Medicine 1/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.